Crosstree Capital Partners Research
Advisory Approach
Crosstree Capital Partners is a boutique healthcare-focused investment banking firm built with a singular and uncompromising thesis: exceptional strategic outcomes require both deep industry expertise and institutional-quality execution. Founded in 1999 and headquartered in Tampa, Florida, Crosstree has spent over two decades designing a firm purpose-built for high-precision M&A execution within healthcare and life sciences. Their hedgehog concept—the singular area where they can be best—is Health Sciences M&A. This laser focus contrasts sharply with generalist investment banks that treat healthcare as one vertical among many.
Crosstree's advisory philosophy centers on the belief that healthcare companies deserve advisors who have spent their careers understanding the regulatory landscape, reimbursement structures, clinical development timelines, and the unique value drivers of pharma services, diagnostics, and healthtech subsectors. Rather than rotating bankers through healthcare, Crosstree has built a career partnership culture where senior bankers develop permanent expertise in specific therapeutic areas and service categories. This results in more informed valuation recommendations, better buyer identification, and superior outcomes for clients navigating complex healthcare transactions.
Sector and Subsector Focus
Crosstree operates across three primary healthcare verticals, each with distinct market dynamics and deal characteristics:
Pharma Services represents the largest portion of Crosstree's deal volume. This includes contract development and manufacturing organizations (CDMOs), clinical research organizations (CROs), patient engagement platforms, and clinical trial logistics providers. Crosstree has particularly deep relationships with PE firms and strategics investing in drug development supply chain optimization. Recent activity includes advising on CRO consolidations, CDMO scale acquisitions, and clinical trial site network buildouts. The pharma services market is experiencing significant M&A activity driven by biotech companies seeking to outsource drug development, manufacturing, and trial execution.
Diagnostics and Tools encompasses clinical diagnostics providers, biomarker development platforms, and diagnostic test manufacturers. Crosstree has advised on transactions spanning from routine chemistry diagnostics to esoteric biomarker testing platforms. This sector appeals to both strategic acquirers (large diagnostics companies, hospital systems) and financial sponsors seeking consolidation opportunities. The subsector benefits from secular growth trends in precision medicine and personalized diagnostics.
Healthcare Technology includes digital health platforms, eClinical software, patient data analytics, and clinical trial technology. This is one of the few M&A boutiques with dedicated coverage to healthtech given the rapid shift toward digital health infrastructure. Crosstree has advised on SaaS acquisitions, platform consolidations, and healthtech-first investors seeking tech-enabled healthcare service plays. The subsector is attractive to both PE firms seeking recurring revenue profiles and strategic acquirers building technology stacks.
Track Record and Deal Volume
Crosstree claims to close more health sciences and pharma services transactions globally than firms 10x its size. The firm reports 200+ health sciences deals and 100+ pharma services deals, with approximately 20+ transactions closed per year in recent years. This consistent deal flow demonstrates strong relationships with both sell-side clients and the buy-side network (PE, strategics, family offices).
Recent notable transactions where Crosstree served as financial advisor include:
- Myonex's acquisition of Creapharm (May 2024) — clinical trial supply consolidation
- Pinnacle Clinical Research's acquisition of Kerwin Medical Center and Cognitive and Research Center of New Jersey (June 2024) — buy-side advisor to LongueVue Capital on clinical trial site network expansion
- Javara Series C funding (May 2025) — advisor to integrated research organization
- Numerous press-release visible deals including Deep 6 AI (acquired by Tempus), Versiti (acquiring Pearl Pathways), and VaxTRIALS (acquired by Emmes)
The firm's deal pipeline is sustained by long-standing relationships with PE firms like LongueVue Capital, Thompson Street Capital, Genstar Capital, and New Mountain Capital who are actively consolidating healthcare service providers and technology platforms.
Process and Fee Structure
Crosstree employs institutional-quality sell-side and buy-side processes. For sell-side engagements, the firm manages comprehensive buyer outreach campaigns, manages data room preparation, and provides transaction support from LOI through close. For buy-side advisory (notably to PE firms like LongueVue Capital), Crosstree provides deal identification, diligence support, and valuation consulting.
The firm does not publicly disclose fee structure, but standard LMM banking practices suggest modified Lehman scale formulas typical for healthcare transactions. Given the firm's focus and the quality of execution, healthcare companies should expect competitive but not discount pricing—typical modified Lehman on enterprise values ranging from $10M to $300M+.
Buyer Network and Deal Typology
Crosstree maintains relationships with a broad buyer ecosystem spanning PE firms, strategics, and family offices. PE firm relationships include LongueVue Capital, Thompson Street Capital, Genstar Capital, New Mountain Capital, Audax, Bain Capital, and numerous smaller regional PE funds focused on healthcare. Strategic acquirers span established diagnostics companies, CRO consolidators, healthtech platforms, and large pharmaceutical companies seeking bolt-on acquisition targets.
The firm advises on both sell-side (founder/PE-backed company sales) and buy-side (PE sponsor acquisition support) mandates. Deal types span M&A acquisitions, add-on acquisitions for platform companies, recapitalizations, and financing advisory.
Competitive Positioning
Crosstree's primary competitive advantage is specialization. In a market where most mid-market banks maintain healthcare practices alongside industrial, technology, and financial services practices, Crosstree has made a strategic bet on healthcare-only focus. This yields several advantages:
-
Industry Relationships: Senior bankers have spent 15-25+ years building relationships with PE firms, strategics, and entrepreneurs specifically in healthcare. This depth is difficult for generalist banks to replicate.
-
Valuation Expertise: Deep understanding of healthcare value drivers—regulatory timelines, reimbursement cycles, clinical trial economics, manufacturing capabilities—enables more accurate valuations and better client education.
-
Market Intelligence: Continuous deal flow in healthcare (20+ deals annually) provides proprietary market insights that inform buyer identification, competitive positioning, and pricing.
-
Execution Speed: Healthcare specialists understand deal timeline complexities (FDA interactions, clinical trial vendor contracts, regulatory approvals) and can compress timelines through anticipated diligence.
Team Structure and Leadership
Crosstree's leadership team consists of three co-founders (Shane Senior, Jeff Ellis, Gordon Ryerson) with 20+ years of M&A experience in healthcare, supplemented by a dedicated group of MDs and Directors. The firm employs approximately 50 professionals across its Tampa headquarters. Key leadership:
- Shane Senior — Managing Director and Co-Founder. Visible speaker and thought leader on AI disruption in clinical trials. Deep relationships with CRO and clinical trial sponsor community.
- Jeff Ellis — Managing Director and Co-Founder. FINRA-registered broker (Series 79, 63). Core M&A execution.
- Gordon Ryerson — Managing Director and Co-Founder
- Gregory Bare — Managing Director. FINRA-registered broker.
- Jason Layton — Managing Director
- Mike Levin — Director of Strategic Advisory & Origination Services
- Ben Garber — Director
- Daniel Niswonger — Director. FINRA-registered broker.
The team's depth in healthcare reflects intentional hiring and retention—unlike banks that rotate junior bankers through coverage areas, Crosstree retains senior people with permanent healthcare expertise.
Not a Fit If
Crosstree is not an appropriate advisor for:
- Non-healthcare businesses. The firm has strategically exited non-healthcare sectors to maintain focus.
- Companies with unclear healthcare applicability (borderline medtech, wellness, consumer health)
- Organizations seeking generalist M&A advice with healthcare as one option. Crosstree is purpose-built for healthcare-only focus.
- Very early-stage companies pre-commercial viability (Crosstree typically engages with revenue-generating or near-commercialization-stage companies)
Geographic Coverage and Market Position
Crosstree operates from Tampa headquarters with national coverage. The firm has completed transactions across all major US markets and has some international transaction experience (evidenced by Myonex/Creapharm cross-border transaction advice). The firm is active in healthcare clusters including Boston (biotech/med device), San Francisco (healthtech), North Carolina (clinical research), and Florida (regional headquarters location).
Institutional Quality and Regulatory Status
All securities transactions are conducted through Crosstree Capital Securities, LLC—a broker-dealer registered with the SEC and a member of FINRA (CRD# 154675) and SIPC. Multiple senior bankers maintain FINRA registrations (Series 79, 63, etc.), indicating institutional-quality compliance and execution. The firm employs a continuous business improvement philosophy focused on industry knowledge, human capital development, project management, and measurable outcomes.